Company Profile: Flow MedTech LLC
Background
Flow MedTech LLC is a medical device company specializing in innovative solutions for cardiovascular procedures, particularly focusing on reducing stroke risk in patients with atrial fibrillation. Established in 2014, the company is headquartered in Cleveland, Ohio, United States. Flow MedTech's mission is to develop and commercialize novel catheter-based devices that address critical needs in the operating room, aiming to enhance patient outcomes and streamline cardiovascular interventions. The company's vision is to become a leading innovator in cardiovascular research on a global scale, providing high-quality and timely treatments through continuous independent research and clinical advancements.
Key Strategic Focus
Flow MedTech's strategic focus centers on the development of minimally invasive endovascular medical devices designed to treat thrombosis-related conditions within the vascular system. A cornerstone of their approach is the ALFAJET platform technology, a versatile thrombectomy device engineered for the safe and effective removal of thrombus from veins, arteries, and arteriovenous dialysis conduits. This technology is particularly pertinent given the global burden of thrombosis, affecting over 70 million patients annually. The company's core objectives include advancing the ALFAJET platform, expanding its applications across various vascular conditions, and achieving broad market adoption. Flow MedTech primarily targets healthcare providers and institutions involved in cardiovascular care, aiming to enhance treatment efficacy and patient safety.
Financials and Funding
Flow MedTech has secured significant funding to support its growth and product development initiatives. In December 2024, the company closed a $5 million seed funding round, which included a previously reported $2 million from friends and family, and new investment from UCM Ventures, the investment arm of the University of Chicago Medical Center. This funding is intended to accelerate the development and launch of their innovative pulmonary embolism (PE) treatment device, focusing on design verification, validation testing, and initiating a first-in-human study.
Pipeline Development
Flow MedTech's product pipeline is centered on the ALFAJET platform, with the initial focus on developing a catheter-based device for the treatment of pulmonary embolism (PE). The device is designed to perform pulmonary angiograms for diagnosing and locating blood clots, disrupt and dissolve clots using an expanding nitinol scaffold that delivers tissue plasminogen activator (TPA), and monitor pulmonary artery pressure to assist in personalized lytic dosing. The company is currently in the design verification and validation testing phase, with plans to initiate a first-in-human study in 2025. Flow MedTech aims to expand the ALFAJET platform to address other vascular conditions, including peripheral artery disease and arteriovenous dialysis conduits, in subsequent development stages.
Technological Platform and Innovation
Flow MedTech's proprietary ALFAJET platform is a multifunctional catheter system that integrates diagnostic, therapeutic, and monitoring capabilities into a single device. This innovative design allows for the identification and localization of blood clots, disruption and dissolution of clots using a nitinol scaffold delivering TPA, and real-time monitoring of pulmonary artery pressure to guide personalized treatment. The platform's versatility and scalability enable its application across various vascular conditions, setting Flow MedTech apart in the medical device industry.
Leadership Team
- Jennifer Fried: Co-founder and CEO. Jennifer is a serial entrepreneur with a background in biomedical engineering. She has previously built and exited a medical device company and is now leading Flow MedTech in its mission to revolutionize PE treatment.
- Dr. Jonathan Paul: Co-founder and Chief Scientific Officer. Dr. Paul is an interventional cardiologist practicing at the University of Chicago Medical Center. He brings extensive clinical expertise to Flow MedTech, having consulted on numerous PE cases.
- Dr. Osman Ahmed: Co-founder and Chief Medical Officer. Dr. Ahmed is an interventional radiologist at the University of Chicago Medical Center. His clinical experience in vascular interventions contributes significantly to the company's development efforts.
Competitor Profile
- Market Insights and Dynamics: The global market for thrombectomy devices is experiencing growth due to the increasing prevalence of thrombosis-related conditions and the demand for minimally invasive treatment options. The market is characterized by a focus on technological innovation, patient safety, and cost-effectiveness.
- Competitor Analysis: Key competitors in the thrombectomy device market include companies like Cardiovascular Systems, Inc., which specializes in peripheral vascular devices, and Medtronic, a global leader in medical devices with a broad portfolio in cardiovascular interventions. These companies offer a range of products targeting vascular conditions, presenting a competitive landscape for Flow MedTech.
Strategic Collaborations and Partnerships
Flow MedTech has established strategic partnerships to enhance its product development and market reach. Notably, the company has collaborated with the University of Chicago Medical Center through its UCM Ventures initiative, securing investment and clinical expertise to advance its PE treatment device.
Operational Insights
Flow MedTech's operational strategy focuses on leveraging its innovative ALFAJET platform to address unmet needs in vascular thrombosis treatment. The company's emphasis on integrating diagnostic, therapeutic, and monitoring functions into a single device aims to improve treatment outcomes and streamline clinical workflows. By targeting a significant market segment with a scalable and cost-effective solution, Flow MedTech positions itself as a competitive player in the medical device industry.
Strategic Opportunities and Future Directions
Looking ahead, Flow MedTech plans to expand the applications of its ALFAJET platform to include treatments for peripheral artery disease and arteriovenous dialysis conduits. The company aims to establish itself as a leader in minimally invasive vascular interventions, continually innovating to meet the evolving needs of healthcare providers and patients.
Contact Information
- Website: flowmedtech.com
- Social Media: LinkedIn – Flow MedTech
